Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/80676
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Circulating microRNAs predict biochemical recurrence in prostate cancer patients
Author: Selth, L.
Townley, S.
Bert, A.
Stricker, P.
Sutherland, P.
Horvath, L.
Goodall, G.
Butler, L.
Tilley, W.
Citation: British Journal of Cancer, 2013; 109(3):641-650
Publisher: Nature Publishing Group
Issue Date: 2013
ISSN: 0007-0920
1532-1827
Statement of
Responsibility: 
L A Selth, S L Townley, A G Bert, P D Stricker, P D Sutherland, L G Horvath, G J Goodall, L M Butler and W D Tilley on behalf of the Australian Prostate Cancer BioResource
Abstract: BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for prostate cancer. Here, we investigated the potential of these molecules to assist in prognosis and treatment decision-making. METHODS: MicroRNAs in the serum of patients who had experienced rapid biochemical recurrence (BCR) (n=8) or no recurrence (n=8) following radical prostatectomy (RP) were profiled using high-throughput qRT-PCR. Recurrence-associated miRNAs were subsequently quantitated by qRT-PCR in a validation cohort comprised of 70 patients with Gleason 7 cancers treated by RP, 31 of whom had undergone disease progression following surgery. The expression of recurrence-associated miRNAs was also examined in tumour tissue cohorts. RESULTS: Three miRNAs - miR-141, miR-146b-3p and miR-194 - were elevated in patients who subsequently experienced BCR in the screening study. MiR-146b-3p and miR-194 were also associated with disease progression in the validation cohort, as determined by log-rank tests and Cox proportional hazards regression. Multivariate analysis revealed that miR-146b-3p possessed prognostic information beyond standard clinicopathological parameters. Analysis of tissue cohorts revealed that miR-194 was robustly expressed in the prostate, elevated in metastases, and its expression in primary tumours was associated with a poor prognosis. CONCLUSION: Our study suggests that circulating miRNAs, measured at the time of RP, could be combined with current prognostic tools to predict future disease progression in men with intermediate risk prostate cancers.
Keywords: microRNA; circulating microRNA; biomarker; prostate cancer; serum; biochemical recurrence
Rights: © 2013 Cancer Research UK
RMID: 0020131439
DOI: 10.1038/bjc.2013.369
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.